Trametinib and Akt Inhibitor GSK2141795 in Treating Patients With Acute Myeloid Leukemia

NCT01907815 · clinicaltrials.gov ↗

PHASE2

Phase

TERMINATED

Status

24

Enrollment

NIH

Sponsor class

Stopped Lack of efficacy.

Conditions

Recurrent Adult Acute Myeloid Leukemia
Untreated Adult Acute Myeloid Leukemia

Interventions

DRUG: Akt Inhibitor GSK2141795
OTHER: Laboratory Biomarker Analysis
DRUG: Trametinib

Sponsor

National Cancer Institute (NCI)